Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleThe dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.
Author(s)Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D.
Journal, Volume, IssueDrug Alcohol Depend. 2013 Feb 1;128(1-2):64-70.
Major outcome(s)THC dose-dependently attenuated cannabis withdrawal.
IndicationDependency/withdrawalAbstract
MedicationDelta-9-THC

BACKGROUND: Prior studies have separately examined the effects of dronabinol (oral THC) on cannabis withdrawal, cognitive performance, and the acute effects of smoked cannabis. A single study examining these clinically relevant domains would benefit the continued evaluation of dronabinol as a potential medication for the treatment of cannabis use disorders.
METHODS: Thirteen daily cannabis smokers completed a within-subject crossover study and received 0, 30, 60 and 120mg dronabinol per day for 5 consecutive days. Vital signs and subjective ratings of cannabis withdrawal, craving and sleep were obtained daily; outcomes under active dose conditions were compared to those obtained under placebo dosing. On the 5th day of medication maintenance, participants completed a comprehensive cognitive performance battery and then smoked five puffs of cannabis for subjective effects evaluation. Each dronabinol maintenance period occurred in a counterbalanced order and was separated by 9 days of ad libitum cannabis use.
RESULTS: Dronabinol dose-dependently attenuated cannabis withdrawal and resulted in few adverse side effects or decrements in cognitive performance. Surprisingly, dronabinol did not alter the subjective effects of smoked cannabis, but cannabis-induced increases in heart rate were attenuated by the 60 and 120mg doses.
CONCLUSIONS: Dronabinol's ability to dose-dependently suppress cannabis withdrawal may be therapeutically beneficial to individuals trying to stop cannabis use. The absence of gross cognitive impairment or side effects in this study supports safety of doses up to 120mg/day. Continued evaluation of dronabinol in targeted clinical studies of cannabis treatment, using an expanded range of doses, is warranted.

Route(s)Oral
Dose(s)
Duration (days)
Participants13 daily cannabis users
DesignOpen study
Type of publicationMedical journal
Address of author(s)Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. rvandrey@jhmi.edu
Full textwww.ncbi.nlm.nih.gov/pubmed/22921474

[Back to Overview]  [IACM Homepage]


up